Latest / DDReg Knowledge Capsule / Winning Thailand FDA Priority Drug Approvals

Transcript

Winning Thailand FDA Priority Drug Approvals · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to Deraide Knowledge Capsule. I want you to imagine
• 0:03
  Speaker 1: a scenario for a second. Put yourself in the shoes
• 0:06
  Speaker 1: of a pharmaceutical sponsor. You are, you know, sitting in
• 0:09
  Speaker 1: a boardroom and you're looking at a drug that is well,
• 0:13
  Speaker 1: it's nothing short of.
• 0:14
  Speaker 2: A breakthrough, right, a real game changer exactly.
• 0:16
  Speaker 1: It addresses this serious unmet medical need. It already have
• 0:20
  Speaker 1: major international approvals under its belt, and your team is
• 0:23
  Speaker 1: ready to expand into Southeast Asia, starting with Thailand as
• 0:27
  Speaker 1: your anchor market. So you apply for a priority review
• 0:30
  Speaker 1: with the Thailand FDA, fully expecting a fast track. The
• 0:34
  Speaker 1: team is you know, poping Champagne. The marketing launch window
• 0:37
  Speaker 1: is set and the revenue projections are just totally locked in.
• 0:40
  Speaker 2: Yeah, everyone's feeling great about it.
• 0:42
  Speaker 1: Right, But Ben, suddenly the queries start piling up in
• 0:45
  Speaker 1: your inbox. The timeline stretches from like months to quarters,
• 0:49
  Speaker 1: and that crucial, highly competitive launch window just it completely vanishes.
• 0:54
  Speaker 2: It is a totally devastating scenario, and frankly, it's one
• 0:57
  Speaker 2: that plays out far more often than people in the
• 0:59
  Speaker 2: regular to our industry care to admit. Oh, yeah, you
• 1:02
  Speaker 2: have the situation where the corporate expectation of speed just
• 1:06
  Speaker 2: you know, clashes violently with the reality of a sovereign
• 1:11
  Speaker 2: regulatory architecture.
• 1:12
  Speaker 1: Yeah, and that is exactly the mission of our deep
• 1:16
  Speaker 1: dive today. We're looking at a comprehensive guide from d
• 1:19
  Speaker 1: dreg Pharma specifically focused on the Thailand FDA Priority Review.
• 1:24
  Speaker 2: Which is a fantastic resource by the way.
• 1:26
  Speaker 1: It really is. We are going to figure out why
• 1:29
  Speaker 1: this supposed fast track is so often an illusion, and
• 1:33
  Speaker 1: more importantly, how to actually secure accelerated drug approval by
• 1:37
  Speaker 1: understanding the hidden triggers and the procedural trapdoors of the
• 1:41
  Speaker 1: Thailand FDA. Right, Okay, let's unpack this because we need
• 1:44
  Speaker 1: to start by understanding the fundamental difference in how Thailand
• 1:47
  Speaker 1: even defines priority review compared to the Western regulatory agencies
• 1:52
  Speaker 1: you might be more familiar with.
• 1:53
  Speaker 2: Yeah, that definition is the root of the entire global misunderstanding. Honestly, no.
• 1:57
  Speaker 1: So.
• 1:58
  Speaker 2: Well, when a pharmaceutical company files, if like the USFDA
• 2:01
  Speaker 2: or the European Medicines Agency, there are formal legally designated
• 2:05
  Speaker 2: priority review pathways. There are specific statutes, published, review clogs,
• 2:12
  Speaker 2: user fees tied to performance goals, and just very clear
• 2:15
  Speaker 2: procedural tracks in Thailand, that formal legally binding equivalent does
• 2:21
  Speaker 2: not actually exist in the same way.
• 2:22
  Speaker 1: Wait, really, so there isn't just like a regulatory box
• 2:26
  Speaker 1: you check that legally binds the agency to a shorter timeline.
• 2:29
  Speaker 2: Not at all. I mean instead, what the industry casually
• 2:32
  Speaker 2: refers to as priority review in Thailand functions much more
• 2:36
  Speaker 2: as a controlled internal acceleration mechanism.
• 2:39
  Speaker 1: Okay, what does that actually mean? In practice?
• 2:41
  Speaker 2: It means it's highly selective triage. The taie FDA uses
• 2:45
  Speaker 2: it to allocate their own finite internal reviewer resources based
• 2:49
  Speaker 2: on three main pillars. Those are therapeutic need, public health relevance,
• 2:53
  Speaker 2: and this is the crucial one, dossier readiness.
• 2:55
  Speaker 1: Ah, dossier readiness.
• 2:57
  Speaker 2: Yeah, they're basically shifting a human reviewer from one desk
• 3:00
  Speaker 2: to another, which means they demand absolute perfection to justify
• 3:04
  Speaker 2: that shift.
• 3:05
  Speaker 1: Okay, I think I get it. So instead of a
• 3:07
  Speaker 1: fast pass at an amusement park that just lets you
• 3:09
  Speaker 1: skip the line, it acts more like a VIP door
• 3:11
  Speaker 1: at a club, but the bouncers at that specific door
• 3:15
  Speaker 1: scrutinize your ID with a microscope.
• 3:18
  Speaker 2: That is a remarkably accurate way to picture it Actually
• 3:21
  Speaker 2: you get pulled to the front of the queue, but
• 3:23
  Speaker 2: the scrutiny of your submission is actually going to be
• 3:25
  Speaker 2: far more intense.
• 3:26
  Speaker 1: Wow. Okay, So what actually gets you pointed toward that
• 3:30
  Speaker 1: VIP door in the first place.
• 3:32
  Speaker 2: Well, there are specific unofficial triggers you have to hit.
• 3:35
  Speaker 2: Your drug needs to target a serious or life threatening
• 3:39
  Speaker 2: indication where there are very limited therapeutic alternatives currently available
• 3:44
  Speaker 2: in the thigh healthcare system makes sense, and you generally
• 3:47
  Speaker 2: need prior approvals and reference jurisdictions. Plus, you need a
• 3:51
  Speaker 2: very strong non clinical rationale that perfectly aligns with your
• 3:54
  Speaker 2: proposed indication. Okay, and fundamentally, you need a perfectly structured dossier.
• 3:59
  Speaker 2: We are talking about adherence to the assian common technical
• 4:02
  Speaker 2: dot CAA, the ACCD or the icch CTD formats.
• 4:06
  Speaker 1: But what happens if a sponsor misjudges that, Like, let's
• 4:09
  Speaker 1: say you have the cure for rare oncology indication. The
• 4:13
  Speaker 1: clinical data is breathtaking, but the structural formatting of your
• 4:17
  Speaker 1: ICCHCTD isn't perfectly mapped to tie expectations.
• 4:22
  Speaker 2: What's fascinating here is that applications without that strict structural
• 4:26
  Speaker 2: alignment instantly revert to standard assessment intensity instantly.
• 4:31
  Speaker 1: They don't even give you a chance to fix it quickly.
• 4:34
  Speaker 2: Nope, the reviewers don't necessarily reject the clinical science outright,
• 4:38
  Speaker 2: but they essentially downgrade your administrative status. Oh wow, Yeah,
• 4:42
  Speaker 2: the early clarification cycles begin, the digital validation emails start
• 4:46
  Speaker 2: flying back and forth, and the acceleration you thought you
• 4:49
  Speaker 2: had just evaporates entirely.
• 4:50
  Speaker 1: That's brutal.
• 4:51
  Speaker 2: The speed exists within the agency, but accessing it reliably
• 4:54
  Speaker 2: requires a level of mechanical precision that, frankly, many global
• 4:58
  Speaker 2: sponsors simply underst to me.
• 5:00
  Speaker 1: So this massive gap between claiming you are eligible for
• 5:03
  Speaker 1: the fast track and actually proving it in the dossier,
• 5:06
  Speaker 1: that is where the process falls apart. Let's talk about
• 5:09
  Speaker 1: the specific pitfalls, because a sponsor listening to this might
• 5:12
  Speaker 1: assume that if a drug is already approved by a
• 5:15
  Speaker 1: major player like the USFDA, Thailand would just wave it through, right, Like,
• 5:19
  Speaker 1: why wouldn't they? If it's safe enough from North America?
• 5:22
  Speaker 1: What is the hold up?
• 5:23
  Speaker 2: It is a logical corporate assumption, but it's a catastrophic
• 5:26
  Speaker 2: regulatory one. Catastrophic Litally, the Thailand FDA is a sovereign
• 5:31
  Speaker 2: regulatory body protecting a specific localized population. A USFDA approval
• 5:37
  Speaker 2: is a strong piece of supporting evidence, absolutely, but it
• 5:41
  Speaker 2: is not a substitute for local scientific justification.
• 5:45
  Speaker 1: Okay, so where do sponsors actually trip up?
• 5:48
  Speaker 2: Well, the DA guide breaks this down into four specific
• 5:51
  Speaker 2: operational dimensions where these eligibility gaps emerge.
• 5:54
  Speaker 1: Let's go through.
• 5:54
  Speaker 2: The first major hurdle is a clinical justification mismatch.
• 5:58
  Speaker 1: Meaning like the trial data doesn't fit the local medical
• 6:02
  Speaker 1: reality precisely.
• 6:03
  Speaker 2: This happens when the indication you're proposing for the time
• 6:06
  Speaker 2: market isn't fully supported by the specific design of your
• 6:09
  Speaker 2: pivotal clinical trial.
• 6:10
  Speaker 1: Give me an example of that.
• 6:11
  Speaker 2: Sure, So, for example, maybe your global trial used the
• 6:15
  Speaker 2: specific comparator drug a standard of care that is widely
• 6:19
  Speaker 2: used in Europe but just isn't the standard of care
• 6:21
  Speaker 2: in Thailand, oh I see. Or perhaps the baseline demographics
• 6:25
  Speaker 2: of your trial cohort just don't match the disease presentation
• 6:28
  Speaker 2: in Southeast Asia and.
• 6:29
  Speaker 1: The TIE reviewers catch that, Oh absolutely, they will immediately
• 6:33
  Speaker 1: flag that mismatch, regardless of what the EMA or us
• 6:38
  Speaker 1: FDA said, because they have to prove it works against
• 6:40
  Speaker 1: what TIE doctors are actually prescribing right now, exactly. Okay,
• 6:43
  Speaker 1: So let's say the clinical design and the comparator drug
• 6:46
  Speaker 1: do align. You still have to prove the drug behaves
• 6:49
  Speaker 1: the same way in a TIE patient as it does
• 6:51
  Speaker 1: in a Western patient.
• 6:52
  Speaker 2: Right, yes, And that leads directly to the second major dimension,
• 6:55
  Speaker 2: regulatory precedent misinterpretation, specifically around bridging.
• 6:59
  Speaker 1: Day bridging data.
• 7:00
  Speaker 2: Okay, yeah. Sponsors often fail to provide adequate bridging data
• 7:04
  Speaker 2: to prove that clinical results generated in say a primarily
• 7:08
  Speaker 2: Caucasian population are metabolically and genetically applicable to an agent
• 7:12
  Speaker 2: population in Thailant.
• 7:14
  Speaker 1: Right, Because we aren't just checking administrative boxes here. We
• 7:17
  Speaker 1: have to explicitly prove metabolic parody. You can't just assume
• 7:21
  Speaker 1: biological uniformity across the globe like diet genetics, average body mass,
• 7:27
  Speaker 1: all of these altered drug efficacy and safety profile.
• 7:30
  Speaker 2: You nailed it. If you don't explicitly prove that your
• 7:33
  Speaker 2: foreign data bridges to the local demographic usually through robust
• 7:38
  Speaker 2: PKPD comparability data, the TIE FDA just hits the breaks.
• 7:43
  Speaker 1: They won't just take your word for it.
• 7:45
  Speaker 2: Definitely not. They will not extrapolate efficacy blindly.
• 7:48
  Speaker 1: Wow. Okay, So let's assume the science is totally bulletproof,
• 7:52
  Speaker 1: the clinical design matches local standards, and your bridging data
• 7:55
  Speaker 1: perfectly demonstrates that the tie demographic processes the drug safely.
• 8:00
  Speaker 2: Okay, perfect scenario.
• 8:00
  Speaker 1: The science is solid. But that doesn't mean the actual
• 8:03
  Speaker 1: paperwork is ready to fly through the system?
• 8:05
  Speaker 2: Does it not at all? And that brings us to
• 8:07
  Speaker 2: the third gap incomplete administrative synchronization.
• 8:11
  Speaker 1: Which sounds incredibly boring. I'm not gonna lie.
• 8:13
  Speaker 2: It sounds deeply mundane to a clinical scientist. Yeah, but
• 8:17
  Speaker 2: it is absolutely deadly to a launch timeline. Well, we're
• 8:20
  Speaker 2: talking about minor metadata tychos, inconsistencies between your product composition
• 8:26
  Speaker 2: and Module three and your local labeling in module one,
• 8:29
  Speaker 2: or just electronic formatting errors in the digital dossier submission.
• 8:34
  Speaker 1: Walk me through the mechanism of that. How does a
• 8:36
  Speaker 1: minor typo derail a priority review? Are they really that pedantic?
• 8:41
  Speaker 2: It's not about being pedantic. It's about the architecture of
• 8:44
  Speaker 2: electronic submission gateways.
• 8:46
  Speaker 1: Oh, the digital systems themselves exactly.
• 8:48
  Speaker 2: The digital systems require absolute consistency. If the labeling claims
• 8:52
  Speaker 2: in your administrative documents don't perfectly character match the clinical
• 8:56
  Speaker 2: indication wording deepier trial data. The system flags it just automatically. Yeah,
• 9:01
  Speaker 2: it triggers endless validation loops. The agency pauses the review
• 9:05
  Speaker 2: the issue of formal query for a correction. You submit
• 9:08
  Speaker 2: the clarification and it goes back into the queue. Oh man,
• 9:11
  Speaker 2: and if that correction doesn't perfectly sync with yet another
• 9:14
  Speaker 2: cross reference document, they ask again.
• 9:16
  Speaker 1: That sounds like a nightmare.
• 9:17
  Speaker 2: It is. Months are lost in administrative purgatory before the
• 9:21
  Speaker 2: actual clinical science is even fully evaluated by the senior reviewers.
• 9:24
  Speaker 1: Which is terrifying when you know millions of dollars are
• 9:28
  Speaker 1: tied to a specific launch window. Absolutely, and yet there
• 9:31
  Speaker 1: is an even larger structural hurdle that precedes all of this,
• 9:35
  Speaker 1: a legal reality that you simply cannot engineer your way around.
• 9:39
  Speaker 2: You're referring to the local importer law. Yes, yeah, that's
• 9:41
  Speaker 2: gap number four. Under tie drug law, direct foreign registration
• 9:46
  Speaker 2: is completely illegal.
• 9:47
  Speaker 1: So I can't just register it from my headquarters.
• 9:50
  Speaker 2: Nope, you cannot sit in a corporate office in London,
• 9:53
  Speaker 2: New York or Basle and hold a drug registration in Thailand.
• 9:58
  Speaker 2: An absolute non to go shable prerequisite is that you
• 10:01
  Speaker 2: must appoint a local licensed importer or manufacturer, which.
• 10:06
  Speaker 1: Makes perfect sense from a sovereignty standpoint. You know, totally,
• 10:09
  Speaker 1: if something goes wrong with the drug in the postmarket phase,
• 10:11
  Speaker 1: the Thai government needs a domestic legal entity to hold accountable,
• 10:15
  Speaker 1: not just some ghost office halfway across the world exactly.
• 10:19
  Speaker 2: But sponsors frequently wait way too long to finalize this partnership.
• 10:23
  Speaker 1: Really, they just overlook it.
• 10:24
  Speaker 2: Yeah, and if you haven't secured, audited, and formalized that
• 10:28
  Speaker 2: local entity before you start submitting your priority paperwork, the
• 10:31
  Speaker 2: application is structurally invalid. It just goes nowhere.
• 10:34
  Speaker 1: Wow. You know, whether you are a regulatory affairs director
• 10:39
  Speaker 1: managing a massive portfolio, or just someone fascinated by how
• 10:43
  Speaker 1: these complex global bureaucracies actually function, The core lession across
• 10:48
  Speaker 1: all of these trapdoors is so clear. If you take
• 10:51
  Speaker 1: away administrative assumptions are the enemy of speed. You cannot
• 10:55
  Speaker 1: assume that what works in one jurisdiction automatically translates to
• 10:58
  Speaker 1: another without doing the foundational groundwork.
• 11:01
  Speaker 2: That's incredibly well said. Assuming flexibility where there is none
• 11:05
  Speaker 2: is just a very expensive strategic mistake.
• 11:07
  Speaker 1: Okay, but let's play Devil's advocate for a second. Sure,
• 11:10
  Speaker 1: let's say a sponsor is incredibly diligent. They navigate all
• 11:13
  Speaker 1: of those hurdles perfectly, They have their local importer locked in,
• 11:16
  Speaker 1: their bridging data is robust, the comparators are correct, and
• 11:19
  Speaker 1: there are absolutely zero metadata typos in the submission gateway.
• 11:23
  Speaker 2: A unicorn submission, right, a unicorn?
• 11:27
  Speaker 1: Why do timelines sometimes still stretch beyond the expected priority window?
• 11:32
  Speaker 1: Here's where it gets really interesting, because now we aren't
• 11:35
  Speaker 1: just talking about administrative friction, No we're not. We're talking
• 11:38
  Speaker 1: about the actual scientific scrutiny, right, and.
• 11:41
  Speaker 2: This is the phase that catches even the most prepared
• 11:44
  Speaker 2: global scientific teams completely off guard.
• 11:47
  Speaker 1: So, going back to our earlier thought, instead of the
• 11:50
  Speaker 1: priority review label acting like a blowtorch that just burns
• 11:53
  Speaker 1: right through the bureaucratic red tape so you can get
• 11:55
  Speaker 1: to the market faster, it doesn't do that at all. Right.
• 11:58
  Speaker 1: It actually acts like a magnifying glass. It takes all
• 12:00
  Speaker 1: the standard scrutiny and focuses it intensely on every microscopic
• 12:05
  Speaker 1: scientific flaw in your application.
• 12:07
  Speaker 2: That is the perfect visualization, and the historical data in
• 12:11
  Speaker 2: the dd RED guide absolutely validates that reality. Yeah, yeah,
• 12:15
  Speaker 2: priority status frequently amplifies scientific scrutiny rather than reducing it.
• 12:20
  Speaker 2: Why is that because you're essentially telling the agency, Hey,
• 12:23
  Speaker 2: this is a critical life saving intervention. Move it to
• 12:26
  Speaker 2: the top of the pile. Ah.
• 12:28
  Speaker 1: So they take it very seriously.
• 12:30
  Speaker 2: Exactly, They're going to assign it to their most senior,
• 12:32
  Speaker 2: rigorous and conservative scientific reviewers right out of the gate.
• 12:36
  Speaker 1: So what exactly are those senior reviewers looking for under
• 12:40
  Speaker 1: that magnifying glass. Where does the scientific friction actually happen
• 12:44
  Speaker 1: at this stage?
• 12:45
  Speaker 2: Well, the most persistent clinical culprits usually live in module
• 12:50
  Speaker 2: three of the dossier, the Chemistry, Manufacturing and Controls section
• 12:55
  Speaker 2: or a CMC. Okay, the Thai FDA is notoriously rigorous
• 12:59
  Speaker 2: about CMS inconsistencies. They will zero in on things like
• 13:03
  Speaker 2: impurity justifications.
• 13:05
  Speaker 1: Like what kind of impurities?
• 13:06
  Speaker 2: Well, if there is a trace impurity or a novel
• 13:09
  Speaker 2: recipient in your manufacturing process, your toxicological justification for why
• 13:13
  Speaker 2: it's safe needs to be absolutely bulletproof.
• 13:15
  Speaker 1: I see.
• 13:16
  Speaker 2: But the biggest CMC issue is usually stability extrapolation.
• 13:19
  Speaker 1: Oh, because of the climate differences.
• 13:21
  Speaker 2: Exactly, thaie Land falls under Climatic Zone IVB, which represents
• 13:25
  Speaker 2: hot and very humid conditions.
• 13:26
  Speaker 1: Right, it's totally different from Europe or North America completely.
• 13:29
  Speaker 2: But sponsors frequently try to submit stability data generated from
• 13:33
  Speaker 2: facilities in temperate climates, perhaps supplementing it with mathematical extrapolation.
• 13:39
  Speaker 1: Let me guess the tire reviewers don't like that.
• 13:42
  Speaker 2: The tire reviewers under a priority mandate will rarely accept
• 13:45
  Speaker 2: that without intense questioning. Wow, they want localized empirical stability
• 13:50
  Speaker 2: data that proves the drug won't degrade on a shelf
• 13:53
  Speaker 2: in Bangkok during the monsoon season, which is fair.
• 13:56
  Speaker 1: I mean you want the drug to actually work when
• 13:58
  Speaker 1: a patient takes it, exactly and beyond the CMC section.
• 14:01
  Speaker 1: The source material highlighted another massive hidden driver of delays,
• 14:05
  Speaker 1: the GMP clearance good manufacturing practice.
• 14:09
  Speaker 2: Yes, this is perhaps the single biggest dumbling block for
• 14:13
  Speaker 2: global sponsors.
• 14:15
  Speaker 1: Why is that so complicated?
• 14:17
  Speaker 2: Well, if you are manufacturing this breakthrough drug overseas, which
• 14:20
  Speaker 2: almost all global sponsors are, that specific overseas facility must
• 14:25
  Speaker 2: have formal recognized GMP clearance from the Thailand FDA.
• 14:29
  Speaker 1: I have to push back on that.
• 14:30
  Speaker 2: Okay, go ahead.
• 14:30
  Speaker 1: If that manufacturing facility in Europe or the US already
• 14:34
  Speaker 1: has a shiny renewed certificate from the EMA or the
• 14:37
  Speaker 1: USFDA explicitly stating they are perfectly GMP compliant. Why on
• 14:42
  Speaker 1: urds does Thailand insist on spending their own limited resources
• 14:46
  Speaker 1: to do a redundant check that seems highly inefficient.
• 14:50
  Speaker 2: It seems inefficient from a corporate perspective for sure, Yeah,
• 14:53
  Speaker 2: But from a sovereign regulatory perspective, it is about autonomous
• 14:57
  Speaker 2: validation and liability.
• 14:58
  Speaker 1: Liability.
• 14:59
  Speaker 2: Yeah, the tailand FDA has its own specific inspection criteria
• 15:03
  Speaker 2: and sovereign mandate.
• 15:04
  Speaker 1: But doesn't an FDA certificate count for anything.
• 15:06
  Speaker 2: An internationally recognized certificate from the FDA or the who
• 15:10
  Speaker 2: supports the application heavily like it builds trust, but it
• 15:14
  Speaker 2: absolutely does not automatically substitute for local clearance. I see,
• 15:18
  Speaker 2: the TIE agency requires their own formal recognition process of
• 15:21
  Speaker 2: that GMP status.
• 15:23
  Speaker 1: So if you submit your priority drug application before you
• 15:25
  Speaker 1: have confirmed the TIE GMP clearance status of your overseas site, you.
• 15:30
  Speaker 2: Will hit an immediate administrative hold. The magnifying glass finds
• 15:33
  Speaker 2: that specific gap instantly. Yeah, the review stops until the
• 15:37
  Speaker 2: facility is cleared, which can take months, depending on agency
• 15:41
  Speaker 2: backlog and whether an on site inspection is deemed necessary.
• 15:44
  Speaker 1: Listening to all of this, the amplified scientific scrutiny, the
• 15:47
  Speaker 1: rigid trap doors, the absolute zero tolerance for electronic formatting errors,
• 15:53
  Speaker 1: the redundant facility clearances, a listener might be wondering, why
• 15:56
  Speaker 1: do pharmaceutical companies willingly subject themselves to this. It's a
• 16:00
  Speaker 1: fair question, like why prioritize the Thailand ARCT so heavily
• 16:03
  Speaker 1: if the expedited process is this brutal and unforgiving.
• 16:07
  Speaker 2: If we connect this to the bigger picture, cracking the
• 16:10
  Speaker 2: Thailand FDA is actually the key to unlocking the entire
• 16:13
  Speaker 2: Southeast Asian commercial region.
• 16:15
  Speaker 1: Ah, the Asian Domino effect.
• 16:17
  Speaker 2: Precisely within the Association of Southeast Asian Nations. Regulatory sequencing
• 16:21
  Speaker 2: is an incredibly high stakes game of strategy.
• 16:24
  Speaker 1: So Thailand is like the boss level you have to
• 16:26
  Speaker 1: beat first.
• 16:27
  Speaker 2: Kind of Yeah, Thailand possesses one of the most mature, rigorous,
• 16:30
  Speaker 2: and respected regulatory authorities in the region. Because of that rigor,
• 16:34
  Speaker 2: Thailand often acts as a reference country or a synchronization
• 16:37
  Speaker 2: node for broader regional submissions.
• 16:40
  Speaker 1: So if you manage to survive the magnifying glass and
• 16:43
  Speaker 1: get it right in Thailand. The other countries in the
• 16:46
  Speaker 1: region are watching your dossier.
• 16:48
  Speaker 2: Yes, authorities in markets like Malaysia, Vietnam and the Philippines
• 16:52
  Speaker 2: really respect the scientific rigor of the Thai FDA.
• 16:56
  Speaker 1: That's huge.
• 16:57
  Speaker 2: It is. If you achieve a synchronized approve dossier in Thailand,
• 17:02
  Speaker 2: you can essentially use that highly vetted, pressure tested ACGD
• 17:06
  Speaker 2: format as the architectural blueprint for parallel filings across the
• 17:11
  Speaker 2: rest of the Asian markets.
• 17:12
  Speaker 1: Oh wow, so you don't have to start from scratch exactly.
• 17:15
  Speaker 2: It prevents massive regional redundancy. You don't have to rebuild
• 17:18
  Speaker 2: the clinical justifications from scratch for every single country.
• 17:21
  Speaker 1: But the inverse must also be true.
• 17:23
  Speaker 2: It is and it is fatal to regional launches. The
• 17:26
  Speaker 2: source material makes it abundantly clear a fragmented dossier will
• 17:30
  Speaker 2: consistently underperform across the board.
• 17:32
  Speaker 1: So a delay in Thailand isn't just a delay in Thailand.
• 17:35
  Speaker 2: Nope. If you struggle in Thailand, if your dossier is
• 17:39
  Speaker 2: full of structural holes, if your bridging data is weak
• 17:42
  Speaker 2: and you get locked in endless multi round clarification loops,
• 17:46
  Speaker 2: that delay doesn't just hurt your time market share. It
• 17:49
  Speaker 2: ripples across your entire asion launched strategy.
• 17:52
  Speaker 1: That is terrifying.
• 17:52
  Speaker 2: You simply cannot build a rapid regional commercial strategy on
• 17:57
  Speaker 2: a fractured regulatory foundation.
• 17:59
  Speaker 1: So let's get incredibly practical here.
• 18:01
  Speaker 2: Okay.
• 18:01
  Speaker 1: If I'm a listener managing a global regulatory launch, or
• 18:04
  Speaker 1: I'm on a clinical strategy team, how do I build
• 18:07
  Speaker 1: a readiness control framework to actually survive this? What is
• 18:11
  Speaker 1: the strategic checklist to get through the taie FDA magnifying
• 18:14
  Speaker 1: glass attack and protect that regional domino effect.
• 18:17
  Speaker 2: The foundation of that framework is extreme, uncompromising structural consistency.
• 18:21
  Speaker 1: Okay, Step one.
• 18:22
  Speaker 2: First, you need to align every single data point from
• 18:26
  Speaker 2: module one the administrative and regional information, all the way
• 18:29
  Speaker 2: through Module three the quality and manufacturing data. No room
• 18:32
  Speaker 2: for errors, none, There can be no orphaned data points.
• 18:35
  Speaker 2: The labeling claims must speak the exact same language as
• 18:38
  Speaker 2: the clinical indication wording deep in the pivotal trial data.
• 18:42
  Speaker 1: Right. Second on the checklist.
• 18:44
  Speaker 2: Explicit bridging justification. As we discussed earlier, you must prove
• 18:48
  Speaker 2: population relevance upfront. Do not wait for them to ask
• 18:52
  Speaker 2: if the drug works in an Asian demographic.
• 18:55
  Speaker 1: You have to be proactive.
• 18:56
  Speaker 2: Yes, provide explicit pharmacokinetic and pharmacodynamic umperability analyses immediately and
• 19:02
  Speaker 2: map that clearly to exposure response alignment.
• 19:05
  Speaker 1: In the third step, which honestly seems to be the
• 19:07
  Speaker 1: most strategic piece of this.
• 19:09
  Speaker 2: Whole puzzle, query anticipation mapping.
• 19:12
  Speaker 1: Anticipation mapping. I like the sound of that.
• 19:15
  Speaker 2: You are essentially playing three dimensional chess with the senior reviewers.
• 19:19
  Speaker 2: You should not be waiting for the tie FDA to
• 19:21
  Speaker 2: ask you the hard questions.
• 19:22
  Speaker 1: You should ask them yourself.
• 19:23
  Speaker 2: Basically, you need to pre identify the likely regulatory fiction
• 19:27
  Speaker 2: points and answer them in the dossier before the submission
• 19:30
  Speaker 2: even goes through the gateway.
• 19:31
  Speaker 1: What kind of friction points should a sponsor anticipate?
• 19:34
  Speaker 2: Well, pre explain your comparator selection logic. Tell them exactly
• 19:38
  Speaker 2: why you chose the standard of care you tested against
• 19:41
  Speaker 2: and why it is relevant to the Thai healthcare system.
• 19:44
  Speaker 1: Oh, that makes sense. Give them the context right.
• 19:47
  Speaker 2: Pre justify your impurity profiles with exhaustive toxicological data. Defend
• 19:53
  Speaker 2: your Zone IVD stability conditions upfront.
• 19:56
  Speaker 1: Don't make them hunt for it exactly.
• 19:59
  Speaker 2: If you know a piece of clinical data is complex
• 20:02
  Speaker 2: or relies heavily on foreign extrapolation, build the narrative defense
• 20:06
  Speaker 2: right into the introduction of the clinical summary.
• 20:08
  Speaker 1: And finally verifying that GMP clearance for the manufacturing site
• 20:11
  Speaker 1: before the digital dossier is even uploaded.
• 20:14
  Speaker 2: Before a single megabyte of data is submitted. Yes, if
• 20:17
  Speaker 2: you fail at any of these checkpoints, you are instantly
• 20:20
  Speaker 2: entering those iterative clarification.
• 20:22
  Speaker 1: Loops and at that point you've lost the advantage totally.
• 20:25
  Speaker 2: At that point, the priority label on your folder is
• 20:27
  Speaker 2: basically meaningless.
• 20:28
  Speaker 1: It is a phenomenal reality check for the industry. You know,
• 20:31
  Speaker 1: we started this deep dive of looking at why the
• 20:33
  Speaker 1: fast track is so often an illusion, and the core
• 20:37
  Speaker 1: lesson here is that in Thailand, speed is not granted
• 20:40
  Speaker 1: just because you have an important life saving drug. Speed
• 20:43
  Speaker 1: is earned, perfectly said, it is earned through dossier maturity,
• 20:47
  Speaker 1: an intense proactive submission discipline. A priority designation doesn't mean
• 20:52
  Speaker 1: less work or an easier grade. It actually requires a
• 20:55
  Speaker 1: flawless execution of the ACTD or ICCHC architecture under heightened scrutiny.
• 21:02
  Speaker 2: It requires a fundamental shift in corporate mindset. Yeah, sponsors
• 21:06
  Speaker 2: really need to stop viewing priority review is a convenient
• 21:09
  Speaker 2: way to bypass bureaucratic scrutiny and start viewing it for
• 21:13
  Speaker 2: what it actually is, an invitation to the most rigorous,
• 21:17
  Speaker 2: high stakes scientific audit of their product.
• 21:20
  Speaker 1: So what does this all mean? If we take everything
• 21:22
  Speaker 1: we've synthesized today from the DTEREG Pharma Guide, the hidden
• 21:25
  Speaker 1: trap doors, the magnifying glass effect of amplified scrutiny, the
• 21:29
  Speaker 1: brutal reality of iterative query cycles, it leads to a
• 21:32
  Speaker 1: really counterintuitive, almost provocative strategic thought. Most make, we established
• 21:37
  Speaker 1: that priority review amplify scientific scrutiny, right, and we know
• 21:40
  Speaker 1: that early administrative formatting errors or clinical justification gaps can
• 21:44
  Speaker 1: trigger endless clarification loops that entirely neutralize any perceived speed advantage. Therefore,
• 21:50
  Speaker 1: and hear me out on this, could a sponsor with
• 21:52
  Speaker 1: a highly complex novel therapy, or maybe a slightly less
• 21:56
  Speaker 1: mature dossier that relies heavily on extrapolation actually achieve a
• 22:01
  Speaker 1: faster overall market entry by deliberately opting for the standard
• 22:05
  Speaker 1: review pathway.
• 22:06
  Speaker 2: Wow, that is a fascinating contrarian strategic.
• 22:10
  Speaker 1: Question, right, because by deliberately avoiding the intense, front loaded
• 22:14
  Speaker 1: magnifying glass of expedited priority status, you might avoid triggering
• 22:19
  Speaker 1: those immediate, aggressive senior level query cycles.
• 22:22
  Speaker 2: I see where you're going with this.
• 22:23
  Speaker 1: By choosing the slow lane, you give the standard reviewers
• 22:26
  Speaker 1: a longer, perhaps less highly pressurized timeline to digest complex
• 22:31
  Speaker 1: bridging data or stability justifications. In a regulatory system where
• 22:35
  Speaker 1: administrative friction and query loops are the ultimate timeline killers.
• 22:39
  Speaker 1: Sometimes deliberately taking the slow lane might actually be the
• 22:41
  Speaker 1: fastest route to the commercial finish line.
• 22:43
  Speaker 2: That completely challenges the baseline instinct of every pharmaceutical executive,
• 22:47
  Speaker 2: which is to always universally push for the fastest designated
• 22:51
  Speaker 2: route available, but honestly based on the actual internal mechanics
• 22:55
  Speaker 2: and resource allocation of the tie FBA, it is a
• 22:59
  Speaker 2: highly viable strategic consideration for complex filings.
• 23:02
  Speaker 1: It's the ultimate regulatory version of the tortoise and the hair.
• 23:07
  Speaker 1: I want you, the listener, to take that thought into
• 23:09
  Speaker 1: your own work.
• 23:10
  Speaker 2: It's definitely something to chew on whether.
• 23:12
  Speaker 1: You are dealing with global drug approvals, supply chain logistics,
• 23:15
  Speaker 1: or any complex bureaucratic system. Sometimes the label that promises
• 23:19
  Speaker 1: speed is just a traptor in disguise. Thank you for
• 23:22
  Speaker 1: joining us on this deep dive until next time. Keep
• 23:25
  Speaker 1: looking past the labels,